Arbutus Biopharma Corp. buy Maxi_Scalibusa
Start price
01.12.21
/
0%
€4.85
Target price
01.12.22
-
Performance (%)
-53.67%
End price
02.12.22
€2.25
Summary
This prediction ended on 02.12.22 with a price of €2.25. The BUY prediction by Maxi_Scalibusa for Arbutus Biopharma Corp. performed very badly with a performance of -53.67%. This prediction was marked as speculative and is excluded from Maxi_Scalibusa's performance statistics.Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Arbutus Biopharma Corp. | -6.015% | -6.015% | 27.899% | 55.280% |
| iShares Core DAX® | -0,68 % | 4,05 % | 2,21 % | 52,79 % |
| iShares Nasdaq 100 | 0,99 % | 10,87 % | 38,04 % | 94,87 % |
| iShares Nikkei 225® | 3,28 % | 13,47 % | 59,00 % | 70,29 % |
| iShares S&P 500 | 0,62 % | 6,20 % | 26,15 % | 68,91 % |
According to Maxi_Scalibusa what are the pros and cons of Arbutus Biopharma Corp. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model
Cons
Comments by Maxi_Scalibusa for this prediction
In the thread Arbutus Biopharma Corp. diskutieren
Buy Arbutus Biopharma Corp.
In the thread Trading Arbutus Biopharma Corp.
Die von Maxi_Scalibusa gewählte maximale Laufzeit wurde überschritten
Stopped prediction by Maxi_Scalibusa for Arbutus Biopharma Corp.
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€3.45
16.11.20
16.11.20
-
16.11.21
16.11.21
-14.81%
17.11.21
17.11.21
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model
